Relief Therapeutics Holding AG

Relief Therapeutics Holding AG is a Swiss commercial-stage biopharmaceutical company focused on developing and commercializing innovative, patent-protected therapies for specialty, rare, and ultra-rare diseases. Founded in 2013 and headquartered in Geneva, the company has established a diversified portfolio that includes both a pipeline of promising drug candidates and revenue-generating, out-licensed products. Its development programs target significant unmet medical needs, particularly in the fields of rare dermatological and metabolic disorders, using advanced drug delivery systems and drug repurposing strategies. Relief’s leading product candidates address conditions such as epidermolysis bullosa and phenylketonuria, while its marketed and out-licensed products cover additional rare and hard-to-treat diseases. With a lean operational structure and collaborations with selected partners, Relief Therapeutics aims to enhance patient outcomes and quality of life, playing a significant role in the advancement of therapies for underserved populations in the global healthcare market.